Helmholtz Munich at ESGCT 2026

Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website

Helmholtz Munich brings 2 presentations to ESGCT 2026 in Hamburg. Its groups work on restoring protein function in disease models. Topics include AAV gene therapies aimed at ferroptosis-related disorders and a designed protein binder that eases disease signs in living animals after the fact.

OrganizationESGCT 2026 Attendance
Helmholtz Munich
Neuherberg, Germany
helmholtz-munich.de
Universities & institutes
Helmholtz Association research centre for environmental health near Munich, with institutes in synthetic biomedicine, metabolism and cell death, and structural biology.
Poster
Wed Oct 28
1:30pm–3:30pm
Development and in vivo validation of AAV-based gene therapies targeting ferroptosis-associated disorders
Disease Models
Vectors and delivery (AAV, lentiviral, LNP)
Poster
Thu Oct 29
2:00pm–4:00pm
Post-translational restoration of protein function with a de-novo binder alleviates disease phenotype in vivo.
Cardiovascular & Muscular diseases

Explore the full ESGCT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Hamburg. Leave your work email and we’ll be in touch.

Privacy

Download the full ESGCT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Helmholtz Munich

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction